Literature DB >> 12895197

Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation.

H S Tomlinson1, S A Corlett, H Chrystyn.   

Abstract

AIMS: To determine the reproducibility and dose-response relationship for urinary salbutamol excretion post inhalation.
METHODS: Fifteen volunteers inhaled either one, two, three, four or five doses of 100 micro g salbutamol on separate days and then seven of these also repeated each of the one, three and five doses on five occasions. After each study dose urine was collected 30 min post inhalation.
RESULTS: The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively. Statistical analysis revealed a linear relationship (P < 0.001). Mean (SD) coefficient of variation after one, three and five doses was 10.5 (3.6), 10.1 (2.7) and 9.4 (2.3)%.
CONCLUSIONS: The 30 min salbutamol urinary excretion post inhalation pharmacokinetic method, to compare inhaled products, is linear with inhaled dose and reproducible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895197      PMCID: PMC1884284          DOI: 10.1046/j.1365-2125.2003.01864.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

Review 1.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

2.  Determination of the relative bioavailability of salbutamol to the lung following inhalation.

Authors:  M Hindle; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

3.  Effects of airway calibre on lung delivery of nebulised salbutamol.

Authors:  B J Lipworth; D J Clark
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

4.  Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler.

Authors:  M Hindle; E M Peers; M Parry-Billings; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1997-03       Impact factor: 4.335

Review 5.  Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes.

Authors:  W P Adams; G Poochikian; A S Taylor; R M Patel; G P Burke; R L Williams
Journal:  J Aerosol Med       Date:  1994

6.  Therapeutic equivalence of three metered-dose inhalers containing salbutamol (Albuterol) in protecting against methacholine-induced bronchoconstriction in children with asthma.

Authors:  J Mallol; V Aguirre; R Rhem; J Rodriguez; M Dolovich
Journal:  Pediatr Pulmonol       Date:  2001-12

7.  Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique.

Authors:  M Hindle; D A Newton; H Chrystyn
Journal:  Chest       Date:  1995-03       Impact factor: 9.410

8.  Volumatic usage: some generic salbutamol metered dose inhalers can be used.

Authors:  J K Chege; H Chrystyn
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

  8 in total
  4 in total

1.  Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.

Authors:  Heather S Tomlinson; Sarah A Corlett; Martin B Allen; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 2.  Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

Authors:  John B Warren
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

3.  Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion.

Authors:  Mohamed E Abdelrahim; Khaled H Assi; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

4.  The Bioavailability of Salbutamol in Urine via Volumatic and Nonvolumatic Valved Holding Chambers.

Authors:  Fanak Fahimi; Farzad Kobarfard; Jamshid Salamzadeh; Atefeh Fakharian; Pegah Abdolahi; Azita Hajhossein Talasaz; Hamid Mahboobi Pour; Shadi Baniasadi; Mohammadreza Masjedi
Journal:  World Allergy Organ J       Date:  2011-11-18       Impact factor: 4.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.